Palliative Care Alongside Active Treatment, Not After It Ends, in Relapsed Myeloma
A man on his fourth line of therapy for relapsed multiple myeloma is still actively fighting his disease, and his oncologist has to decide whether asking a palliative care team to join now, rather than after treatment options run out, sends the message he fears it will — or corrects a documented pattern where patients like him get referred later than almost anyone else with cancer.
Q.E. has three grandchildren under six who call the infusion suite "grandpa's office," a nickname that started as a joke during his first-line treatment four years ago and has stuck through two relapses since. He is two weeks into a fourth-line carfilzomib-based regimen for relapsed/refractory multiple myeloma, still actively pursuing disease control with real remaining treatment options, and visibly startled when his oncologist raised the idea of involving palliative care alongside this cycle rather than after future lines fail — his first response was to ask whether this meant she thought he was dying.
That reaction reflects a documented, real pattern in hematologic malignancy specifically, not an idiosyncratic fear. Referral-timing studies, including work characterizing hospice and palliative-care use in blood cancers, have repeatedly found that patients with hematologic malignancies are referred to palliative and hospice services substantially later in their disease course than patients with solid tumors — often within the final days of life rather than the weeks-to-months window more typical in solid-tumor oncology, a disparity attributed partly to the relapsing-remitting trajectory itself and partly to oncologists' hesitancy to raise palliative care mid-treatment. El-Jawahri and colleagues' 2016 randomized trial in JAMA, integrating palliative care early alongside patients undergoing hematopoietic stem cell transplantation — a population still pursuing aggressive, potentially curative treatment, not comfort care — found that the integrated group's quality of life declined less over the transplant hospitalization than the control group's — a smaller decrease rather than an outright improvement, which is the honest way to state it — alongside lower depression symptoms, with the six-month follow-up showing sustained lower depression and post-traumatic stress symptoms but no significant separation on anxiety. It is not, though, evidence drawn from a patient like Q.E.: every participant was undergoing stem cell transplantation, and he is on a fourth-line carfilzomib regimen with no transplant planned. The population overlaps him on the thing that matters here — active, aggressive treatment — and misses him on the setting entirely.
Q.E.'s own relationship to his diagnosis has always run through fighting it in front of his grandchildren rather than around them — he brought the youngest to a chemo education session two relapses ago, over his daughter's initial objection, because he wanted her to see the infusion suite as an ordinary place rather than a frightening one. That same instinct is what made today's reaction sharper than a purely clinical read of his chart would have predicted: to him, a new team joining his care doesn't read as support, it reads as a crack in the version of the story he has been carefully building for his family since the first diagnosis.
In the infusion suite, between his carfilzomib cycles
I think we should involve palliative care now, explicitly framed as support alongside his continued treatment, not a signal anything has changed about his prognosis. El-Jawahri's trial showed real benefit from early integration in patients undergoing stem cell transplant — still pursuing aggressive, potentially curative treatment, not comfort care. I'll concede up front that Q.E. isn't a transplant patient, so I'm extending the finding rather than applying it, and what carries across is the principle that integration and active treatment aren't in tension, not the effect size. What is directly about him is the referral-timing data: hematologic malignancy patients are documented to get referred later than almost any other cancer population. I don't want Q.E. to become another data point in that same pattern.
I agree with the evidence, but I watched his face when I raised this ten minutes ago — his first question was whether I think he's dying. That reaction is real information too. I've built four years of trust with him around fighting this disease, and I'm genuinely worried that introducing palliative care today, however well-intentioned, could damage his hope in ongoing treatment if I don't handle the framing with real care.
I don't think you two are actually disagreeing about whether palliative care should be involved — you both think it should be. I think this is a framing and timing-of-conversation question, not a clinical disagreement. What if his symptom burden becomes the entry point instead of the word "palliative" itself — his neuropathy, his inconsistently controlled pain, his steroid-related insomnia are all real, present problems a symptom-management team can help with today, independent of prognosis. Introducing the team around what they can do for him right now, rather than leading with what the referral might imply about his future, may get you both what you're each weighting most heavily.
Agreed: palliative care referral placed, introduced to Q.E. specifically around his neuropathy, inconsistent pain control, and steroid-related insomnia, framed explicitly as a symptom-management team joining his existing care alongside continued carfilzomib treatment, not a change in his prognosis or a signal treatment was failing.
Not fully resolved: the Hematologist-Oncologist remained genuinely uncertain, even after the reframe, whether Q.E. would experience the referral as reassuring or as confirmation of his own fear despite the careful framing — she planned to check in directly at his next visit specifically about how the conversation landed for him, treating that as still open rather than settled by today's plan.